Jennings provided 2026 guidance: "We expect revenue within the range of $1.4 billion to $1.5 billion with adjusted gross margin between 26% and 27%." Adjusted EBITDA for 2026 is projected at $200 ...
The application of several high-throughput genomic and proteomic technologies to address questions in cancer diagnosis, prognosis and prediction generate high-dimensional data sets. The multimodality ...
Don’t start with moon shots. by Thomas H. Davenport and Rajeev Ronanki In 2013, the MD Anderson Cancer Center launched a “moon shot” project: diagnose and recommend treatment plans for certain forms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results